12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Herceptin trastuzumab: Completed Phase III enrollment

Genentech Inc., South San Francisco, Calif.
Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Product: Herceptin trastuzumab ( RG597); Tykerb ( Tyverb - EU) lapatinib
Business: Cancer
Molecular target:...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >